Education
About Us
Working with TipRanks
Follow Us
FibroBiologics, Inc. (FBLG)
NASDAQ:FBLG
FBLG Stock Chart & Stats
$0.34
-$0.09(-3.98%)
At close: 4:00 PM EST
$0.34
-$0.09(-3.98%)
Day’s Range― - ―
52-Week Range$0.39 - $3.89
Previous CloseN/A
Volume56.64K
Average Volume (3M)978.93K
Market Cap
$16.83M
Enterprise Value$25.97M
Total Cash (Recent Filing)$4.87M
Total Debt (Recent Filing)$7.11M
Price to Earnings (P/E)―
Beta0.59
Next Earnings
Nov 18, 2025EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding51,456,078
10 Day Avg. Volume1,423,641
30 Day Avg. Volume978,931
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)24.04
Price to Sales (P/S)0.00
P/FCF Ratio-5.44
Enterprise Value/Market Cap1.54
Enterprise Value/Revenue46.88
Enterprise Value/Gross Profit365.77
Enterprise Value/Ebitda-1.51
Forecast
1Y Price Target
$4.50Price Target Upside1223.53% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe company continues to make important progress advancing preparation for manufacturing the fibroblast-based spheroids candidate CYWC628 for the forthcoming Phase 1/2 trial in DFU patients.
Research And DevelopmentThe company has demonstrated positive IND-enabling progress for fibroblast spheroid utilization in the treatment of chronic-relapse psoriasis, reflecting the potential breadth of fibroblast therapies and upside.
Therapeutic ApplicationsThe Bone Marrow Organoid platform has potential for treatment of cancer as well as aging-related immune decline.
Bears Say
Stock PerformanceThe stock has been down over -80% YTD, while the NBI is up over +20% YTD.
FibroBiologics, Inc. News
FBLG FAQ
What was FibroBiologics, Inc.’s price range in the past 12 months?
FibroBiologics, Inc. lowest stock price was $0.39 and its highest was $3.89 in the past 12 months.
What is FibroBiologics, Inc.’s market cap?
FibroBiologics, Inc.’s market cap is $16.83M.
When is FibroBiologics, Inc.’s upcoming earnings report date?
FibroBiologics, Inc.’s upcoming earnings report date is Nov 18, 2025 which is in 10 days.
How were FibroBiologics, Inc.’s earnings last quarter?
FibroBiologics, Inc. released its earnings results on Jul 31, 2025. The company reported -$0.12 earnings per share for the quarter, the consensus estimate of -$0.12 by $0.
Is FibroBiologics, Inc. overvalued?
According to Wall Street analysts FibroBiologics, Inc.’s price is currently Undervalued.
Does FibroBiologics, Inc. pay dividends?
FibroBiologics, Inc. does not currently pay dividends.
What is FibroBiologics, Inc.’s EPS estimate?
FibroBiologics, Inc.’s EPS estimate is -0.12.
How many shares outstanding does FibroBiologics, Inc. have?
FibroBiologics, Inc. has 51,456,078 shares outstanding.
What happened to FibroBiologics, Inc.’s price movement after its last earnings report?
FibroBiologics, Inc. reported an EPS of -$0.12 in its last earnings report, expectations of -$0.12. Following the earnings report the stock price went up 1.563%.
Which hedge fund is a major shareholder of FibroBiologics, Inc.?
Among the largest hedge funds holding FibroBiologics, Inc.’s share is Fund Evaluation Group, LLC. It holds FibroBiologics, Inc.’s shares valued at 0.
Company Description
FibroBiologics, Inc.
FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
FBLG Stock 12 Month Forecast
Average Price Target
$4.50
▲(1223.53% Upside)
Technical Analysis
Bioline RX Ltd Sponsored ADR
―
Curis
―
Synlogic
―
Lexaria Bioscience
―
Processa Pharmaceuticals
―
Ownership Overview
14.18% Insiders
4.05% Mutual Funds
0.07% Other Institutional Investors
78.97% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---